Tilray Brands Inc

Tilray Brands Q3 tops expectations with record revenue, a narrowed loss, and a positive EPS, yet market sentiment remains cautious amid high valuation and ongoing net‑loss pressure.

Tilray Brands faces a pivotal pivot: Wall Street shifts from “Sell” to “Hold” as the company expands into Australia and partners with Cheba Hut, yet its earnings lag, valuation strains, and volatile stock keep investors wary. Explore whether this me…

Tilray Brands expands its medical cannabis portfolio in Australia, partners with Breckenridge Distillery for U.S. growth, yet faces stock volatility amid market uncertainty.

Tilray Brands surges as cannabis moves to Schedule III, launching Tilray Medical USA to tap a growing U.S. medical market—investors eye a new growth wave.

Tilray Brands Inc. reported a record $210 million in Q1 fiscal 2026 revenue and turned a profit of $1.5 million, marking a significant turnaround for the company.